Protara Therapeutics, Inc. (TARA)
NASDAQ: TARA · Real-Time Price · USD
2.610
+0.020 (0.77%)
Nov 5, 2024, 11:17 AM EST - Market open

Protara Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 2018 - 2017
Period Ending
Jun '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 2018 - 2017
Selling, General & Admin
17.5218.6220.7426.422.463.95
Upgrade
Research & Development
26.7324.9916.8121.0911.983.88
Upgrade
Operating Expenses
44.2543.6137.5547.4934.447.83
Upgrade
Operating Income
-44.25-43.61-37.55-47.49-34.44-7.83
Upgrade
Interest Expense
-----0.03-
Upgrade
Interest & Investment Income
3.563.191.110.240.5-
Upgrade
EBT Excluding Unusual Items
-40.69-40.42-36.44-47.25-33.98-7.83
Upgrade
Impairment of Goodwill
---29.52---
Upgrade
Pretax Income
-40.69-40.42-65.95-47.25-33.98-7.83
Upgrade
Net Income
-40.69-40.42-65.95-47.25-33.98-7.83
Upgrade
Net Income to Common
-40.69-40.42-65.95-47.25-33.98-7.83
Upgrade
Shares Outstanding (Basic)
1411111173
Upgrade
Shares Outstanding (Diluted)
1411111173
Upgrade
Shares Change (YoY)
22.64%0.64%0.24%55.28%180.66%-76.99%
Upgrade
EPS (Basic)
-2.94-3.57-5.86-4.21-4.70-3.04
Upgrade
EPS (Diluted)
-2.94-3.57-5.86-4.21-4.70-3.04
Upgrade
Free Cash Flow
-33.42-37.6-26.58-35.1-24.29-5.49
Upgrade
Free Cash Flow Per Share
-2.41-3.32-2.36-3.12-3.36-2.13
Upgrade
EBITDA
-43.9-43.27-37.3-47.37-34.34-7.81
Upgrade
D&A For EBITDA
0.350.340.250.120.10.02
Upgrade
EBIT
-44.25-43.61-37.55-47.49-34.44-7.83
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.